Olatorepatide Shows Promising Weight Loss Results at EASD 2026 Conference #Italy #Milan #Hansoh_Pharma #Olatorepatide #Diabetes_Conference

Hansoh Pharma's Olatorepatide Shows 19.3% Weight Loss in Phase III Study at EASD 2026 #None #Milan #Hansoh_Pharma #EASD_2026 #Olatorepatide

EASD 2026: Phase III Results of Olatorepatide Show Significant Weight Loss Benefits #Italy #Milan #Hansoh_Pharma #EASD #Olatorepatide

Significant Weight Loss Achieved with Olatorepatide in Phase III Study Presented at EASD 2026 #Italy #Milan #Hansoh_Pharma #EASD #Olatorepatide

Olatorepatide Shows 19.3% Weight Loss After One Year: Insights from EASD 2026 #Italy #Milan #Hansoh_Pharma #GLP-1/GIP #Olatorepatide

Olatorepatide Shows Promising Weight Loss Results at EASD Annual Meeting #Italy #Milan #Hansoh_Pharma #Olatorepatide #EASD_Meeting

Significant Weight Loss Data from Olatorepatide Revealed at EASD 2026 Conference #Italy #Milan #WeightLoss #Olatorepatide #Hansoh

Substantial Weight Loss Achieved with Hansoh's Olatorepatide in Phase III Clinical Trial at EASD #Italy #Milan #Hansoh_Pharma #EASD_2026 #Olatorepatide